Ex­clu­sive: No­vo Nordisk al­lies it­self with one of the buzzi­est groups in biotech, launch­ing a mul­ti-pronged at­tack at dis­cov­er­ing new drugs

No­vo Nordisk es­tab­lished its R&D rep around its in-house ex­per­tise that ul­ti­mate­ly birthed the GLP-1 block­buster semaglu­tide and pushed it to ma­jor-mar­ket fran­chise sta­tus. But …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER